The North America Leukemia Therapeutics market has been estimated at USD 1.85 Billion in 2016 and is projected to reach USD 2.83 Billion by 2021, at a CAGR of 8.9% during the forecast period from 2016 to 2021. Leukemia is the cancer of the WBC or the bone marrow, which occurs due to abnormal increase in the count of white blood cells. It is identified by the type of the blood cell that is affected (lymphocytic or myelocytic) and by the spread of the diseases (either acute or chronic). It accounts for almost 0.0148% of all the men and 0.009% of all the women worldwide.
Browse market data tables and in-depth TOC of the North America Leukemia Therapeutics Market to 2021 @ http://www.marketdataforecast.com/market-reports/north-america-leukemia-therapeutics-market-823/
The North American market for Leukemia Therapeutics is mainly increasing due to increasing occurrence of leukemia. Also, there is raise in awareness regarding the disease, drugs and treatments due to increasing involvement of R&D in coming up with new ways of treatments and drugs. Due to this, the market is highly driven. But due to high cost of treatment and drugs, there is a chance of drop in the market growth.
North America market for Leukemia Therapeutics is segmented based on disease condition, diagnosis, treatments and drugs. By disease condition, the market is further sub-segmented into chronic lymphatic leukemia, acute lymphatic leukemia, chronic myeloid leukemia and acute myeloid leukemia. By diagnosis, the market is further sub-segmented into CT scan, biopsy and MRI. By treatments, the market is further sub-segmented into chemotherapy, radiation therapy, immunotherapy, surgery, targeted therapy, bone marrow transplant and stem cell therapy. By drugs, the market is further sub-segmented into Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat. By disease condition, chronic myeloid leukemia dominated the overall therapeutic market owing to high prevalence rate. Stem cell therapy and bone marrow transplant are the emerging trends in leukemia therapeutic market. Gleevec was the one of the major market growth contributors, in the drugs category.
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/north-america-leukemia-therapeutics-market-823/request-sample
Geographically, North America market for Leukemia Therapeutics is segmented into U.S.A and Canada. North America holds the largest share in global market, followed by Europe. A number of factors such as rising prevalence of leukemia, and increasing penetration of companies into the market with increasing R&D involvement are creating opportunities for market growth in Leukemia Therapeutics market in the North American region.
Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb , Eisai Co. Ltd, Biogen Idec , ERYtech Pharma , Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc. are the major players of North America Leukemia Therapeutics market.
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases